Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Survival of This Lymphoma Type Tied to Demographics
Clin Lymphoma Myeloma Leuk; ePub 2017 Feb 16; Murthy, et al
Incidence and survival of anaplastic lymphoma kinase positive anaplastic large cell lymphoma (ALK positive ALCL) can vary substantially depending on patient demographics, according to a study involving more than 1,600 individuals.
Participants were diagnosed with ALK positive ALCL over a 12-year period ending in 2013. Investigators looked at incidence and overall survival. Among the results:
- Incidence increased significantly with age.
- Compared with whites, incidence was higher in blacks and lower in American Indians and Asian/pacific Islanders.
- 5-year overall survival was 15% in patients >80 years of age; it was 29% in those 61 to 80 years of age.
- This rate was 54% in patients 41 to 60 years of age; it was 69% in those 20 to 40 years of age.
- Overall survival was 50% in whites, 38% in blacks, 43% in Asian/pacific Islanders, and 36% in American Indians.
- Radiation treatment and being diagnosed later in the study period was linked with lower mortality.
- Older age, advanced disease stage, and black race were linked with higher mortality.
Murthy G, Hamadani M, Bhatt V, Dhakal I, Mehta P. Systemic anaplastic lymphoma kinase positive anaplastic large cell lymphoma: A population-based analysis of incidence and survival. [Published online ahead of print February 16, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.02.003.